Connect with us

Micro Cap Insider

Custodianship/SPAC; the Rise of Energy 1 Corp (OTCMKTS: EGOC)

Published

on

Energy 1 Corp (OTCMKTS: EGOC) is another exciting RM play getting noticed by penny stock speculators with volume picking up rapidly.  EGOC is another custodianship/SPAC from David Lazar. Reverse Merger stocks are proving to be more explosive than biotech and EGOC has all the markings of a enormous coming Reverse Merger. After years of dormancy EGOC filed an 8k stating David Lazar and Custodian Ventures, LLC has been appointed as the custodian of the Company. Microcapdaily reported on another David Lazar SPAC XMET which saw an enormous run back in the day. 

On May 15, 2021, Shanghai Yicheng Culture, a subsidiary of Pangbo Group, announced the acquisition of Energy 1 Corp. of the United States (EGOC) The acquisition not only gives Pangbo Group a controlling interest in (EGOC) Energy 1 Corp., but also opens the door for Pangbo to enter the international capital market. The Pangbo Group has stated a highly ambitious vision of “complete the OTC listing on the US Capital Growth Enterprise Market within 6 months; complete the US Nasdaq transfer listing within 3-6 months; return to the main board of the Hong Kong Stock Exchange for IPO within 12 months. Achieve within five years, a market value of 100 billion yuan and a tax value of tens of billions. At the same time, with Pangbo Group as the core, based on high-end services, build a world-class innovative high-end service platform to help the development of national brands, implement the Healthy China 2030 national strategy and the national innovation-driven development strategy, and promote high-quality economic development. 

Energy 1 Corp (OTCMKTS: EGOC) is a clean shell and perfect merger candidate that was orginally incorporated under the name of Northwest Horizon Corporation in the State of Nevada, United States of America on February 5, 2003. The name was changed to Dairy Fresh Farms Inc. on August 11, 2005. Dairy Fresh Technologies Ltd. had the exclusive license in Canada to develop and exploit the patented formula for a healthy milk-based product” Dairy Fresh Farms”. The Company launched 2-liter regular milk and a 1-liter lactose free product with Canada Safeway stores in Western Canada during the year ended December 31, 2005 as a test launch. 

JULY 20, 2020 AFTER-MARKET NEWS:

$EGOC’S first SEC filing since 2012 is an 8-K showing David Lazar custodianship.

David Lazar; the King of OTC SPAC’s!! – David Lazar is a private investor and since February of 2018, Mr. Lazar has been the managing member of Custodian Ventures LLC, where he specializes in assisting distressed public companies. Since March 2018, David has acted as the managing member of Activist Investing LLC, which specializes in active investing in distressed public companies. David has a diverse knowledge of financial, legal and operations management; public company management, accounting, audit preparation, due diligence reviews, and SEC regulations.  

In recent years there have been a number of hugely successful David Lazar custodianship/SPAC RM deals that have even spawned the message board; David Lazar, OTC SPAC’s/CUSTODIAN Plays on Investorshub.com.  

Investor Sentiment in EGOC is high. EGOC’S first SEC filing since 2012 is an 8-Kshowing David Lazar Custondianship

To get an inside look at EGOC Subscribe to Microcapdaily.com immediately by entering your Email below

EGOC

Translated from here: On May 15, 2021, Shanghai Yicheng Culture, a subsidiary of Pangbo Group, announced the acquisition of Energy 1 Corp. of the United States (EGOC) and announced the acquisition of the company’s stock code: NASDAQ (NASDAQ) EGOC. The acquisition not only gave Pangbo Group a controlling interest in (EGOC) Energy 1 Corp., but also opened the door for Pangbo to enter the international capital market. In order to quickly build a blue ocean of Pangbo capital transactions and realize corporate capital fission, Pangbo Group, starting from Heze, plans to organize and launch 100 Pangbo listing start-up briefings in 100 cities across the country. 

Pangbo Group’s 100-city linkage listing launch briefing has successively entered Sanya in Hainan, Weifang in Shandong, Xuchang in Henan, Yancheng in Jiangxi, Tangshan in Hebei, and will soon enter Hangu in Tianjin, Xinxiang in Henan, Houma in Shanxi, Songyuan in Jilin, Hengyang in Hunan and other places. Pangbo Group Hundred-City Linkage IPO launch briefing is currently being carried out in an orderly manner… 

Pangbo Group takes smart e-commerce retail, innovative healthcare, and big data cloud innovation applications as its three pillar industries. It unites with China Capital Innovation Group, Huaao Investment Group, and Baiyi Group, through market-oriented operations and capitalized operations, and strives to build The global high-end technological innovation service platform has achieved the three strategic goals of OTC listing on the GEM of the United States, transfer of listing on the Nasdaq of the United States, and return to the main board of the Hong Kong Stock Exchange for IPO. 

Pangbo Group’s path to capital is not a temporary motive, nor is it single-handedly, but to follow the trend and have multiple guarantees. It is not only escorted by China Capital Group, Huaao Investment Group, and Baiyi Group, but also united with Nanding (Shoubao Medical) Medical Technology Co., Ltd., Zhu’s Pharmaceutical Group, Xianjuhui Supply Chain, and Tangshan Jukang Hospital of Traditional Chinese Medicine, Tangshan Taizhimei Agriculture and Animal Husbandry Co., Ltd., etc., through the strong alliance of multiple parties, improve the rapid development of economic capital, and achieve resource sharing and win-win cooperation.Image 

Headquartered in Hong Kong Special Administrative Region, China Venture Holdings Group is a professional investment banking financial service provider, mainly providing comprehensive financial advisory for enterprises, domestic enterprises’ IPO in Hong Kong, domestic enterprises’ mergers and acquisitions and listing in Hong Kong, domestic enterprises’ international investment and financing docking, and traditional enterprise modernization Upgrade and other services. China Capital Group has a strong shareholder background, spanning both China and Hong Kong. With its superior shareholder background, China Capital Group enjoys an entire international financing platform, including participation in international financing projects, domestic companies listing in Hong Kong or abroad, etc. At present, China Ventures is operating a number of large-scale financing projects in first-tier cities, including areas such as big health, new materials, Internet +, new agriculture, environmental protection, high-tech, new retail, etc., and successfully helped many high-quality projects to complete their trip to Hong Kong IPO and mergers and acquisitions.Image 

Mr. Zhang Jinyuan, Chairman of Huaao Investment Group, once stated at the launch briefing meeting of Pangbo Group’s 100-city linkage listing that Huaao Investment Group and Pangbo Group will work together and develop together. The three major combinations of Pangbo Group, China Capital Group, and China Australia Investment Group can not only help the rapid development of Pangbo Group’s capital, but also stimulate market innovation and accelerate the strategic upgrade of group services. 

Pangbo Group also has high-end technology, film and television media, education and training, corporate consulting, brand management and other business sectors. As we all know, new retail, big health, big data, film and television are all areas of capital pursuit. According to relevant statistics, since 2010, the proportion of funds raised by e-commerce retail companies in the Nasdaq sector has increased year by year. Affected by the global epidemic in 2020, innovative healthcare companies have become the new favorites of investment, occupying half of the capital flow. 

The three major goals of Pangbo Group’s capital operation are: complete the OTC listing on the US Capital Growth Enterprise Market within 6 months; complete the US Nasdaq transfer listing within 3-6 months; return to the main board of the Hong Kong Stock Exchange for IPO within 12 months . Achieve within five years, a market value of 100 billion yuan and a tax value of tens of billions. At the same time, with Pangbo Group as the core, based on high-end services, build a world-class innovative high-end service platform to help the development of national brands, implement the Healthy China 2030 national strategy and the national innovation-driven development strategy, and promote high-quality economic development. 

For More on EGOC Subscribe Right Now!

Energy 1 Corp is another exciting RM play getting noticed by penny stock speculators with volume picking up rapidly.  EGOC is another custodianship/SPAC from David Lazar. Reverse Merger stocks are proving to be more explosive than biotech and EGOC has all the markings of a enormous coming Reverse Merger. After years of dormancy EGOC filed an 8k stating David Lazar and Custodian Ventures, LLC has been appointed as the custodian of the Company. Microcapdaily reported on another David Lazar SPAC XMET which saw a major run back in the day.  On May 15, 2021, Shanghai Yicheng Culture, a subsidiary of Pangbo Group, announced the acquisition of Energy 1 Corp. of the United States (EGOC) The acquisition not only gives Pangbo Group a controlling interest in (EGOC) Energy 1 Corp., but also opens the door for Pangbo to enter the international capital market. The Pangbo Group has stated a highly ambitious vision of “complete the OTC listing on the US Capital Growth Enterprise Market within 6 months; complete the US Nasdaq transfer listing within 3-6 months; return to the main board of the Hong Kong Stock Exchange for IPO within 12 months. Achieve within five years, a market value of 100 billion yuan and a tax value of tens of billions. At the same time, with Pangbo Group as the core, based on high-end services, build a world-class innovative high-end service platform to help the development of national brands, implement the Healthy China 2030 national strategy and the national innovation-driven development strategy, and promote high-quality economic development. We will be updating on EGOC when more details emerge so make sure you are subscribed to Microcapdaily so you know what’s going on with EGOC.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: we hold no position in EGOC either long or short and we have not been compensated for this article.

Continue Reading
Click to comment

Leave a Reply

Your email address will not be published. Required fields are marked *

Featured

Reunion Neuroscience Inc.’s (NASDAQ: REUN) Take-Private Agreement and Its Impact on Mental Health Solutions

Published

on

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development.

Reunion Neuroscience (NASDAQ: REUN) shares jump 119% as they announce an exciting new development. The clinical-stage biopharmaceutical company has entered into a take-private transaction with MPM BioImpact, representing a significant milestone for Reunion Neuroscience. The transaction is valued at $13.1 million, a 43.1% premium to Reunion’s common shares’ 30-day volume-weighted average price.

Going private is a significant step for Reunion Neuroscience, as it means that a sizeable private-equity group or consortium of private-equity firms will purchase or acquire the stock of the publicly traded corporation.

To Discover the Inside Scoop on REUN, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Under the terms of the Arrangement Agreement, all holders of outstanding common shares of Reunion will be entitled to receive $1.12 in cash for each share held immediately before the effective time of the Arrangement. However, the agreement’s closing is subject to several conditions, which must be met before the transaction can be completed.

Hostile takeover?

While management and the board think it is a significant milestone achieved, others think differently – an investor rights law firm, Halper Sadeh LLC, is currently investigating it… The sale of Reunion Neuroscience to affiliates of MPM BioImpact for $1.12 per share in cash is currently being investigated by Halper Sadeh LLC.

The investigation concerns whether Reunion and its board of directors violated the federal securities laws and/or breached their fiduciary duties to shareholders by failing to, among other things: (1) obtain the best possible consideration for Reunion shareholders; (2) determine whether MPM is underpaying for Reunion; and (3) disclose all material information necessary for Reunion shareholders to assess and value the merger consideration adequately. On behalf of Reunion shareholders, Halper Sadeh LLC may seek increased consideration for shareholders, additional disclosures and information concerning the proposed transaction, or other relief and benefits.

Reunion Neuroscience’s stock performance has been relatively volatile in recent years. The stock’s median target price, according to analysts’ forecasts, is $5.00, but there is a wide range of estimates, with a high of $20.00 and a low of $0.73. The current consensus among polled investment analysts is to buy $REUN stock. However, they’re a pre-revenue clinical-stage biopharmaceutical company, which means the last earnings reported a loss in the current quarter’s earnings per share – they’ve yet to generate any significant revenue. Until recently, shareholders experienced a significant decline in the stock’s value this year and were down ~54%  prior to the acquisition. There are ~9M shares in the float, with ~28% and ~13% held by insiders and institutional investors, respectively.

Overall, investors should carefully consider the potential risks and rewards associated with investing in Reunion Neuroscience, considering the wide range of price estimates and the company’s current financial performance. Thorough research and the advice of a financial professional are recommended before making any investment decisions.

We will update you on REUN when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by Gerd Altmann from Pixabay

Continue Reading

Featured

Marker Therapeutics, Inc. (NASDAQ: MRKR) Unveils Exciting Pre-Clinical Findings of MT-601 T Cell Therapy in Lymphoma Cells

Published

on

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601.

Marker Therapeutics, Inc. (Nasdaq: MRKR) shares surged by 45% as the company released positive pre-clinical Data on one of its candidates, MT-601. They tested it on lymphoma cells in the lab, and the results showed that MT-601 can kill lymphoma cells resistant to another treatment called CD19 CAR T therapy, which is fascinating news considering many patients who receive CD19 CAR T therapy still experience a relapse within a year. 

“We have recently developed a long-term in vitro model to monitor the interaction of T cells with cancerous cells. Data from a lymphoma cell line utilizing this model demonstrated that MT-601 inhibited the growth of lymphoma cells as well as the growth of CD19 CAR-resistant lymphoma cells,” said Eric A. Smith, Ph.D., Director of Research and Development at Marker Therapeutics. Marker has posted further details about this preclinical study on the Investor Relations section of its website.

Dr. Smith continued, “Specifically, we have developed an in vitro model which reproduces the CD19 antigen-negative tumor that causes relapse and observed the following:

To Discover the Inside Scoop on MRKR, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

In this in vitro model, 98% of lymphoma cells were eliminated after a CD19-targeting CAR T cell product was administered.

While the CAR T cells significantly controlled lymphoma cell growth, we observed that three weeks after the start of anti-CD19 CAR T cell administration, a population of lymphoma cells resistant to CD19 CAR T cell administration started to grow.

These CD19 CAR-resistant lymphoma cells were tested for CD19 expression. They were shown to be negative for the CD19 surface antigen, which explained why they were no longer controlled with a second administration of anti-C19 CAR T cells, thus recapitulating the antigen-negative relapse observations in CAR relapsed/refractory lymphoma patients.

However, when MT-601, with its broad antigen recognition (Survivin, NY-ESO-1, WT-1, PRAME, MAGE-A4, SSX2), was added to this anti-CD19 CAR T cell resistant cell population, complete growth inhibition was observed.

These data highlight that MT-601 can potentially eliminate CD19 CAR T cell refractory tumors, indicating that MT-601 might offer a viable therapeutic option for lymphoma patients that have relapsed from previous CAR T cell interventions.”

MT-601 targets multiple substances on cancer cells and may provide longer-lasting results than CD19 CAR T therapy. Marker Therapeutics has started a clinical trial to test MT-601 on lymphoma patients who have relapsed after CD19 CAR T therapy or cannot receive it. The early lab results showed that MT-601 could inhibit the growth of lymphoma cells, including those resistant to CD19 CAR T therapy. The initial results have shown remarkable promise, and the team is thrilled to advance the testing of MT-601 in further clinical trials to evaluate its effectiveness and safety.

About Marker Therapeutics, Inc.

Marker Therapeutics is a company currently in the advanced stages of clinical research for developing innovative treatments in immuno-oncology. Their primary focus is on creating next-generation immunotherapies that utilize T cells, a type of immune cell, to target and fight against hematological malignancies (cancers of the blood, such as leukemia and lymphoma) and solid tumors (cancers that form in tissues or organs). These therapies aim to harness the immune system’s power to specifically recognize and eliminate cancer cells, offering potential new treatment options for patients with these types of cancers.

Capital structure

Marker Therapeutics has an outstanding total of 8.8M shares and presents a relatively small float of 6.64M shares available for public trading. Insiders hold approximately 12.82% of the shares, while institutional investors hold around 22.63%. Examining their trading history, the average volume typically hovers around 100,000 shares. In light of the positive news today, the trading activity trended much higher, with an impressive 27M shares traded at time of writing. This translates to a 270-fold increase compared to their average volume, also 4x their float.

It is essential to recognize the high volatility and rapid movements associated with Marker Therapeutics’ stock, primarily driven by the limited availability of shares. Such stocks tend to attract the interest of day and swing traders, given their propensity for swift gains or losses based on trading strategies. As evidence, a single positive news catalyst in the biotech sector can trigger a substantial surge in stock price and exponentially increase trading volume to unprecedented levels.

We will update you on MRKR when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PDPics from Pixabay

Continue Reading

Emerging Markets

Aclarion Inc (NASDAQ: ACON): A Breakthrough Partnership

Published

on

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic.

Aclarion, Inc. (NASDAQ: ACON) shares rocketed 157% Tuesday morning after their commercialization agreement with the London Clinic. The London Clinic is UK’s most renowned independent, private hospital, established 1932 with their Spine Clinic being the first specialist spinal unit based in England back in 1997.

“With a focus on providing the very best healthcare outcomes, The London Clinic is an ideal customer for Aclarion as the company works to deliver the Nociscan solution to physicians and patients around the world,” said John Sutcliffe MD, Neurosurgeon and Founder of London Spine Clinic. “The engagement with Aclarion will allow London Spine Clinic to continue offering the high-quality care our patients have come to expect. Patients need a careful assessment, diagnosis, and understanding of the different treatment options. Aclarion’s innovative Nociscan solution will enable us to objectively assess biomarkers associated with low back pain and enhance the precision of each diagnosis.”

More on Nociscan Technology

Aclarion, Inc.’s Nociscan Technology is an innovative medical solution that aims to revolutionize the diagnosis of disc-related conditions. They leverage biomarkers and proprietary augmented intelligence algorithms to help physicians identify the location of chronic low back pain.

What’s exciting is its advantages over the current standard of care. It offers a non-invasive approach, ensuring patient comfort and safety. Given it’s non-invasive, that also means 0 pain with 0 radiation (typically associated with traditional discography). The best part is it can seamlessly integrate into standard lumbar MRI protocols, making it a convenient and efficient option for healthcare providers. 

To Discover the Inside Scoop on ACON, Subscribe to Microcapdaily.com Right Now by entering your Email in the box below.

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

The procedure takes approximately 25-45 minutes, thoroughly evaluating spinal discs without compromising accuracy. Additionally, Nociscan technology offers significant cost savings, with a list price of $1,450, making it an affordable alternative to traditional discograms. Overall, Aclarion, Inc.’s technological advances represent a significant push forward in disc-related diagnostic techniques, prioritizing patient well-being, convenience, and affordability.

https://twitter.com/TigerLineTrades/status/1663527784143093762?s=20

Nociscan Study

They also recently completed a study that spanned two years and involved 78 patients at a single site. The success rate soared to an impressive 85% for patients whose treatment strategy aligned with the disks identified by Nociscan. This represented a remarkable 22% improvement over patients whose treatment strategy did not consider the insights provided by Nociscan.

Aclarion expressed confidence that the results of the trial demonstrate the potential of Nociscan to assist physicians in successfully treating DLBP. Dr. Matthew Gornet, orthopedic surgeon and lead author of the study, enthusiastically endorsed Nociscan, stating, “The two-year surgical outcomes of the clinical trial provide unequivocal evidence of its effectiveness, particularly with regards to the primary endpoint, the Oswestry Disability Index (ODI). I firmly believe that Nociscan has the potential to revolutionize the standard of care and accurately aid all physicians treating chronic low back pain.”

It is worth noting that although Nociscan was performed on all patients in the study, it was not part of the surgical decision-making process, as highlighted by the company.

Conclusion

The commercial agreement between Aclarion, Inc. and the prestigious London Clinic signifies a significant milestone for both parties, carrying the potential for global recognition, revenue growth, and scalability. By integrating Aclarion’s innovative Nociscan Technology, the London Clinic demonstrates its commitment to delivering cutting-edge healthcare to optimize patient well-being and enhance clinical outcomes. Furthermore, the partnership’s success holds the potential for scaling Nociscan Technology to other institutions and markets, propelling Aclarion, Inc. to become a global leader in non-invasive medical technologies while driving substantial revenue growth.

We will update you on ACON when more details emerge, so make sure you are subscribed to Microcapdaily to know what’s happening in the markets!

Subscribe to Our 100% Free Penny Stock Newsletter. We Have Something Big Coming!

Disclosure: We have not been compensated for this article/video. MicroCap Daily is not an investment advisor; this article/video does not provide investment advice. Always do your research, make your own investment decisions, or consult with your nearest financial advisor. This article/video is not a solicitation or recommendation to buy, sell, or hold securities. This article/video is our opinion, is meant for informational and educational purposes only, and does not provide investment advice. Past performance is not indicative of future performance.

Image by PIRO from Pixabay

Continue Reading

Trending

© All rights reserved.

Sign up now for our 100% FREE Penny Stock Newsletter

Privacy Policy. we will never share your email with anyone.